NCT06506955 2026-03-11Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Taiho Oncology, Inc.Phase 2/3 Enrolling by invitation15 enrolled
NCT04507503 2026-03-10Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsTaiho Oncology, Inc.Approved for marketing